An antidepressant already on the market could pave the way toward more affordable and accessible treatment for people with a symptomatic COVID-19 infection.
A new clinical trial using the psychiatric drug fluvoxamine (brand name Luvox) showed promise in a Washington University trial in reducing serious outcomes for people with the virus.
Researchers compared the course of illness for those who took the drug compared to a placebo group. According to the study, there was no “clinical deterioration” out of 80 participants in the trial who took fluvoxamine compared to six out of 72 in the placebo group.
Read more on themighty.com